Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2741682 | 1.00 | HRH3 (0.67) | HRH3CYP2D6CYP2C9HIF1AHDAC1 | |
| SCHEMBL27854081 | 1.00 | HRH3 (0.67) | HRH3CYP2D6CYP2C9HIF1AHDAC1 | |
| Hydrochloric Acid SCHEMBL10374042 | 0.98 | HRH3 (0.64) | HRH3CYP2D6CYP2C9HIF1AHDAC1 | |
| Hydrochloric Acid SCHEMBL7654075 | 0.98 | HRH3 (0.64) | HRH3CYP2D6CYP2C9HIF1AHDAC1 | |
| Hydrochloric Acid SCHEMBL228646 | 0.98 | HRH3 (0.64) | HRH3CYP2D6CYP2C9HIF1AHDAC1 | |
| SCHEMBL2787677 | 0.98 | HDAC1 (0.67) | HRH3CYP2D6CYP2C9HIF1AHDAC1 | |
| Hydrochloric Acid SCHEMBL3870152 | 0.96 | HDAC1 (0.65) | HRH3CYP2D6CYP2C9HIF1AHDAC1 | |
| SCHEMBL20828408 | 0.94 | HDAC1 (0.62) | HRH3CYP2D6CYP2C9HIF1AHDAC1 | |
| SCHEMBL10074441 | 0.90 | HDAC1 (0.62) | HRH3CYP2D6CYP2C9HIF1AHDAC1 | |
| SCHEMBL3275253 | 0.87 | HRH3 (0.69) | HRH3CYP2D6CYP2C9HIF1AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4305940-A | Benzamides with local anaesthetic and antiarrhythmic activity, salts, and method of preparation thereof and pharmaceutical compositions therefrom | B.B.R. BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1981-12-15 | — | — | US | claimed |
| US-11203582-B2 | Benzamide derivatives for inhibiting endoplasmic reticulum (ER) stress | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2021-12-21 | — | — | US | disclosed |
| US-20200199094-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING ENDOPLASMIC RETICULUM (ER) STRESS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2020-06-25 | — | — | US | disclosed |
| WO-2018119362-A2 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICALS INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| CN-104817519-B | The derivant of one class CA-4, its preparation method and medical usage thereof | 中国药科大学 | 2016-11-16 | — | — | CN | disclosed |
| US-20160046616-A1 | NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-02-18 | — | — | US | disclosed |
| US-20150259329-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA CELLULAR THERAPIES INC (US) | 2015-09-17 | — | — | US | disclosed |
| CN-104817519-A | CA-4 derivatives as well as preparation method and medical application of CA-4 derivatives | UNIV CHINA PHARMA | 2015-08-05 | — | — | CN | disclosed |
| US-9056837-B2 | Heterocycle compounds and uses thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| WO-2014145642-A9 | NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-11-13 | — | — | WO | disclosed |
| US-20100173924-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES INC. | 2010-07-08 | — | — | US | disclosed |
| EP-2166858-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | Intra-Cellular Therapies, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008153959-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| CN-101321754-A | Novel compounds II | ASTRAZENECA AB (SE) | 2008-12-10 | — | — | CN | disclosed |
| US-20080255106-A1 | Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080207904-A1 | Imatinib base, and imatinib mesylate and processes for preparation thereof | SICOR INC. | 2008-08-28 | — | — | US | disclosed |
| EP-1934217-A1 | NEW COMPOUNDS II | Astra Zeneca AB (SE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007040439-A1 | NEW COMPOUNDS II | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| CN-1004628-B | Process for preparing benzothiazine dioxide derivatives | 美国辉瑞有限公司 | 1989-06-28 | — | — | CN | disclosed |
| US-4305940-A | Benzamides with local anaesthetic and antiarrhythmic activity, salts, and method of preparation thereof and pharmaceutical compositions therefrom | B.B.R. BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1981-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046616-A1 | NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY | NFE2L2, KEAP1, GSTK1 | HRH3 3158/4885CYP2D6 4084/4885CYP2C9 4698/4885 |
| US-20150259329-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | PYGB, BACE1, APP | HRH3 1749/4885CYP2D6 2144/4885CYP2C9 1213/4885 |
| US-20100173924-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | PYGB, BACE1, APP | HRH3 1688/4885CYP2D6 2351/4885CYP2C9 1322/4885 |
| US-20080255106-A1 | Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders | GSK3B, PYGB, GSK3A | HRH3 1683/4885CYP2D6 2280/4885CYP2C9 2833/4885 |
| US-20200199094-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING ENDOPLASMIC RETICULUM (ER) STRESS | HSPA5, TMBIM6, BAD | HRH3 2363/4885CYP2D6 4738/4885CYP2C9 4827/4885 |
| US-11203582-B2 | Benzamide derivatives for inhibiting endoplasmic reticulum (ER) stress | HSPA5, TMBIM6, BAD | HRH3 2363/4885CYP2D6 4738/4885CYP2C9 4827/4885 |
| US-20080207904-A1 | Imatinib base, and imatinib mesylate and processes for preparation thereof | ABL1, ABL2, MET | HRH3 2733/4885CYP2D6 258/4885CYP2C9 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.